Company: ANTX
Filing Date: 2025-03-25
Form Type: 10-K
Source: 0000950170-25-044366
Chunk: 157

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-03-25
Form: 10-K
Item: Item 1B
Chunk 157
---
 Accounting Officer)
     
    March 25, 2025

    Lucy O. Day

    /s/ Maggie FitzPatrick
     
    Lead Independent Director
     
    March 25, 2025

    Maggie FItzPatrick

    /s/ Kabeer Aziz
     
    Director
     
    March 25, 2025

    Kabeer Aziz

    /s/ Gilbert L. Marks
     
    Director
     
    March 25, 2025

    Gilbert L. Marks

    /s/ Patricia (Patty) Martin
     
    Director
     
    March 25, 2025

    Patricia (Patty) Martin

    /s/ Rob Readnour
     
    Director
     
    March 25, 2025

    Rob Readnour

    /s/ Melvin Spigelman
     
    Director
     
    March 25, 2025

    Melvin Spigelman

    /s/ Stephanie Wong
     
    Director
     
    March 25, 2025

    Stephanie Wong

    /s/ Joseph Zakrzewski
     
    Director
     
    March 25, 2025

    Joseph Zakrzewski

94

INDEX TO FINANCIAL STATEMENTS

    Report of Independent Registered Public Accounting Firm (PCAOB ID: 238)
    F-2

    Balance Sheets as of December 31, 2024 and 2023
    F-3

    Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023
    F-4

    Statements of Stockholders’ Equity for the years ended December 31, 2024 and 2023
    F-5

    Statements of Cash Flows for the years ended December 31, 2024 and 2023
    F-6

    Notes to the Financial Statements
    F-7

F-1

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of AN2 Therapeutics, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of AN2 Therapeutics, Inc. (the “Company”) as of December 31, 2024 and 2023, and the related statements of operations and comprehensive loss, of stockholders’ equity and of